|Bid||1.9500 x 2900|
|Ask||2.0700 x 900|
|Day's Range||1.9301 - 2.1000|
|52 Week Range||1.0100 - 2.1550|
|Beta (5Y Monthly)||1.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 23, 2022 - Mar 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.13|
Adma Biologics (ADMA) delivered earnings and revenue surprises of -25% and 9.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
First Quarter 2022 Total Revenues Were Approximately $29.1 Million, an 81% Increase Over First Quarter 2021 Increases Full Year 2022 Total Revenue Guidance to $130 Million or More From $125 Million Gross Margin Growth and Narrowing Net Losses Expected Throughout 2022 and Beyond RAMSEY, N.J. and BOCA RATON, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing a
A look at the shareholders of ADMA Biologics, Inc. ( NASDAQ:ADMA ) can tell us which group is most powerful. Large...